BRIEF REPORT

Successful High-Dose Radiation Treatment for Chemo-Resistant Oral Squamous Cell Carcinoma in a Kindler's Syndrome Patient

Yuka Kimura, Atsushi Tanemura, Yuma Hanaoka, Eiji Kiyohara, Mari Wataya-Kaneda, Manabu Fujimoto, Katsuto Tamai¹, Keisuke Tamari², Yuji Seo², Kazuhiko Ogawa²

Departments of Dermatology, ¹Stem Cell Therapy Science, and ²Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan

Dear Editor:

The patient was a 54-year-old female who had been diagnosed with Kindler syndrome¹. She noticed vulnerable white moss and erosion on her lip, which was histologically diagnosed as squamous cell carcinoma (Fig. 1A, B). No metastasis was detected; however, the tumor inoperably extended to her lip, buccal mucosa, and hard palate. Those lesions were initially treated with a selective arterial infusion of peplomycin through bilateral retrograde catheter. Once the elevated lesions became flat, recurrence was observed within 2 months. Irrespective of sequential intraarterial cisplatin chemotherapy commonly used for head and neck tumors treatment uplifting of the hard palate with fine granular white moss occurred (Fig. 1C). Computed tomography detected further invasion with bone destruction in the right maxillary sinus (Fig. 1D). As a third line treatment, we initiated intensity-modulated radiation therapy (IMRT) at a dose of 70 Gy/35 Fr (Fig. 1E). At one month after treatment, the tumor mass was significantly reduced in size and the oral lesions had noticeably improved. Followingly, the white elevated moss disappeared and magnetic resonance imaging could not detect the invasive lesion into the right maxillary sinus (Fig. 1F, G). No recurrence and distant metastasis have been observed 5 months after IMRT treatment.

Squamous cell carcinoma is reported to occur in nearly 70% of Kindler syndrome patients over 45 years of age, and the prognosis is reportedly poor due to the tumor agressiveness². Recent report demonstrated that squamous cell carcinoma of the lip was successfully treated in 17 of 24 cases with selective administration of high-concentration peplomycin through the facial and maxillary artery³. However, the insufficient chemotherapy as the present case might be due to substantial tumor aggressiveness and/or phenotypic conversion to chemo-resistance.

Locally-intense radiotherapy was selected, because it highdose irradiation could reportedly shrink oral squamous cell carcinoma arising in Kindler syndrome patients, irrespective of persistent mucosal disorder⁴. Based on recent development of irradiation devices, IMRT enabled selective and curative high-dose radiation therapy at the target sites with minimal adverse effects⁵. Differing from conventional irradiation methods, IMRT utilizes multiple radiation beams of non-uniform intensities which are modulated according to intensity maps resulting in strengthening the conformal radiation dose to the target lesions. In addition, particle beam therapy with stronger energy in comparison to radiation has been clinically applied in anticancer therapy. Although radiotherapy is known not to be commonly accepted for the treatment of genodermatosis patients due to toxicity and secondary carcinogenesis, high dose IMRT without redundant irradiation to

Received November 25, 2019, Revised March 3, 2020, Accepted for publication March 25, 2020

Corresponding author: Atsushi Tanemura, Department of Dermatology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan. Tel: 81-6-6879-3031, Fax: 81-6-6879-3039, E-mail: tanemura@derma.med.osaka-u.ac.jp

ORCID: https://orcid.org/0000-0002-5239-8474

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Copyright © The Korean Dermatological Association and The Korean Society for Investigative Dermatology




Fig. 1. (A) Vulnerable white moss and overlying erosion on the right side of the lip (arrowheads). (B) H&E staining demonstrated atypical squamous cells with the formation of cancer pearls deeply proliferated from the epithelium on the upper portion (×20). The inset shows a high-powered view of the area in the red rectangle (×200). (C) The elevated lesion with white moss on the hard palate was apparent. (D) Direct tumor invasion into the right maxillary sinus and nasal cavity through the bottom of the maxillary bone in a view of the coronal section (red circle). (E) A map of intensity-modulated radiation therapy (IMRT) irradiation indicating that the right eye ball was out of focus. The rainbow map was designed as non-uniform irradiation area. Total estimated dose on the center was 7,494.9 cGy. (F) The white elevated moss disappeared and was replaced by slightly necrotic tissue (arrowheads). (G) The tumor was not detected by magnetic resonance imaging after IMRT treatment.

the surrounding tissue was effective and well-tolerable in the present case. Since the follow-up period is relatively short as 5 months, further care should be taken to avoid the possible occurrence of secondary malignancies in the future. This experience will add significant new evidence on the treatment of chemo-resistant squamous cell carcinoma of the oral cavity arising in genodermatosis patients. We received the patient's consent form about publishing all photographic materials.

CONFLICTS OF INTEREST

The authors have nothing to disclose.

FUNDING SOURCE

None.

ORCID

Yuka Kimura, https://orcid.org/0000-0003-3843-8166 Atsushi Tanemura, https://orcid.org/0000-0002-5239-8474 Yuma Hanaoka, https://orcid.org/0000-0003-3550-4981 Eiji Kiyohara, https://orcid.org/0000-0002-0436-4296 Mari Wataya-Kaneda, https://orcid.org/0000-0001-7280-9560 Manabu Fujimoto, https://orcid.org/0000-0002-3062-4872 Katsuto Tamai, https://orcid.org/0000-0003-0953-7157 Keisuke Tamari, https://orcid.org/0000-0002-2290-1905 Yuji Seo, https://orcid.org/0000-0001-7808-6850 Kazuhiko Ogawa, https://orcid.org/0000-0001-8872-7690

REFERENCES

- Kindler T. Congenital poikiloderma with traumatic bulla formation and progressive cutaneous atrophy. Br J Dermatol 1954;66:104-111.
- Cardin-Langlois E, Hanna D, St-Amant M, Croteau F. Invasive squamous cell carcinoma of the hand in a patient with Kindler syndrome: case report and literature review. Can J Plast Surg 2010;18:e41-e43.
- Fujimura T, Takahashi K, Kambayashi Y, Furudate S, Hidaka T, Kakizaki A, et al. Retrospective investigation of cutaneous squamous cell carcinoma on the lip treated with peplomycin administered through a superficial temporal artery. Anticancer Res 2017;37:1885-1889.
- Caldeira A, Trinca WC, Flores TP, Costa AB, Brito Cde S, Weigert KL, et al. A Kindler syndrome-associated squamous cell carcinoma treated with radiotherapy. Rep Pract Oncol Radiother 2016;21:532-536.
- 5. Gupta T, Agarwal J, Jain S, Phurailatpam R, Kannan S,

Ghosh-Laskar S, et al. Three-dimensional conformal radiotherapy (3D-CRT) versus intensity modulated radiation therapy (IMRT) in squamous cell carcinoma of the head and neck: a randomized controlled trial. Radiother Oncol 2012;104: 343-348.

https://doi.org/10.5021/ad.2021.33.4.384



Drug-Induced Immune Hemolytic Anemia Caused by Postoperative Cefotetan Administration

Seha Park, Shinyoung Song, Jinok Baek, Hyangjoon Park

Department of Dermatology, Gachon University Gil Medical Center, School of Medicine, Gachon University, Incheon, Korea

Dear Editor:

Drugs can induce almost any hematologic disorder that affects white blood cells, red blood cells (RBCs), platelets, and the coagulation system. Although the clinical manifestation of drug-induced immune hemolytic anemia (DIIHA) is usually mild, it may progress to acute severe hemolytic anemia (HA) and death. There is an increasing number of reports of second and third-generation cephalosporins causing clinical hemolysis¹. Cefotetan is a second-generation cephalosporin used frequently in postoperative condition. Here, we report a case of cefotetan-induced immune hemolytic anemia in a Korean (CIIHA).

A 68-year-old male with a small nasal nodule was diagnosed as basal cell carcinoma was referred to our hospital for further treatment. We removed the remaining lesion and the defect was repaired with a nasolabial flap (Fig. 1). Intravenous cefotetan 2 g daily was administered to the patient postoperatively for 7 days. Before discharge, the patient developed sudden mild fever (37.8°C) and fell down due to dizziness. Other symptoms including nausea, weakness, dark urine color, drowsiness, and pale appeared successively. During his hospitalization, there were no symptoms other than stomach discomfort. His he-

moglobin (Hb) and hematocrit were 3.5 g/dl and 12.8%, respectively. The total serum bilirubin was 6.86 mg/dl (Table 1). There was no evidence of internal bleeding upon physical examination. His reticulocyte and red cell production index were 2.93% (normal, $1\% \sim 2\%$) and 0.916. We excluded chronic anemia, and acute gastrointestinal bleeding as a possible diagnosis. Therefore, we doubted a drug-induced condition. The patient was transferred to the Medical Intensive Care Unit. The patient's serum did not react with the antibody-detection RBCs. The



Fig. 1. A 1.0 cm \times 1.0 cm sized erythematous nodule with brown pigments on the nose (A) and at the 3 months follow-up (B). We received the patient's permission about publishing all photographic materials.

Received February 12, 2020, Revised April 29, 2020, Accepted for publication May 4, 2020

Corresponding author: Hyangjoon Park, Department of Dermatology, Gachon University Gil Medical Center, 21 Namdong-daero 774beon-gil, Namdong-gu, Incheon 21565, Korea. Tel: 82-32-460-2763, Fax: 82-32-460-2374, E-mail: parkhjmd@naver.com

ORCID: https://orcid.org/0000-0002-2143-0080

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Copyright @ The Korean Dermatological Association and The Korean Society for Investigative Dermatology